Jamin Morrison, MD

Learn how melanoma patients choose treatment by trusting a care team, preserving identity, and leaning on support to shape personal goals.

Learn how non-inferior subcutaneous cancer therapy matches IV efficacy while saving time, easing discomfort, and empowering patient choice.

When treatments work equally well, clinicians weigh patient preferences against logistics to improve cancer care efficiency and experience.

Subcutaneous immunotherapy for melanoma cuts clinic time, boosts comfort and autonomy, and helps patients keep work, family, and passions.

Patients welcome subcutaneous immunotherapy for shorter clinic time, with the same monitoring—reshaping expectations of cancer care.

Discover how subcutaneous melanoma immunotherapy replaces IV infusions, cutting clinic time while delivering the same proven drug and results.

IV vs subcutaneous nivolumab feels similar, experts say—watch the same toxicity labs, and calm mild injection-site reactions with ice or Benadryl.

This segment highlights a real-world patient perspective on immunotherapy tolerability in advanced melanoma. Ms. Haupert shares that she experienced minimal side effects during treatment, primarily limited to intermittent fatigue that required occasional rest days. She reflects on feeling fortunate to maintain a relatively stable quality of life throughout therapy. She also notes ongoing monitoring of thyroid function following treatment, illustrating how some immune-related effects may require continued follow-up even after therapy completion. Dr. Morrison provides broader clinical context, explaining that many patients receiving immunotherapy experience mild or manageable side effects, while a smaller proportion may develop more significant toxicities that require intervention. He emphasizes that these effects are generally well understood and can be managed effectively with appropriate monitoring and care. Overall, this segment reinforces variability in patient experience while highlighting the importance of ongoing surveillance in advanced melanoma.

Learn which immunotherapy side effects matter most—rash, breathing changes, diarrhea, fatigue—and why labs track liver, kidney, thyroid inflammation.

New guidelines back FDA‑approved subcutaneous therapy as effective as IV, letting patients choose faster, easier dosing without losing safety.

Switching from IV to subcutaneous injection eases hard vein access, cuts clinic time, and boosts comfort with faster treatment and fewer side effects.

See how subcutaneous immunotherapy cuts clinic time to minutes, streamlining pharmacy prep and avoiding IV access while monitoring toxicity.

Clinical trial data shows subcutaneous nivolumab matches IV effectiveness in kidney cancer, enabling faster, easier immunotherapy dosing.

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

Discover how modern immunotherapy awakens T cells to shrink melanoma tumors, tracked by PET scans and used after surgery to prevent relapse.

In this segment, Ms. Haupert shares the key questions and concerns she had when discussing treatment options for advanced melanoma. The conversation highlights how patients often prioritize understanding treatment effectiveness, potential side effects, and how therapy may impact their daily lives. She reflects on the importance of logistical considerations, including time commitment, frequency of visits, and overall burden of treatment. Dr. Morrison facilitates the discussion to emphasize how these factors influence patient decision making and underscore the need for clear, patient-centered communication. The segment illustrates that beyond clinical outcomes, patients are also focused on how treatment fits into their routines and responsibilities. This exchange reinforces the value of shared decision making in advanced melanoma, where aligning treatment choices with patient preferences and expectations is essential to optimizing both clinical and quality-of-life outcomes.

In this segment, Ms. Popolo discusses key priorities during initial visits with patients newly diagnosed with advanced melanoma. The conversation focuses on the importance of patient education, including helping individuals understand their diagnosis, treatment options, and the overall care pathway. She emphasizes setting clear expectations early, particularly around treatment goals, potential outcomes, and what patients may experience during therapy. The discussion also highlights the need to address common concerns, including side effects and the emotional impact of diagnosis, while ensuring that information is delivered in a clear and supportive manner. Dr. Morrison guides the exchange to underscore the role of the advanced practice provider in bridging clinical information with patient understanding. This segment reinforces the importance of communication, shared decision making, and establishing a strong foundation of trust at the start of the advanced melanoma treatment journey.

In this segment, Ms. Haupert shares her personal experience navigating advanced melanoma, offering valuable insight into the patient journey from diagnosis through treatment. She describes how her care was initiated, including whether she began with intravenous immunotherapy or transitioned to a subcutaneous approach, and reflects on what that experience was like at different stages of her treatment. The discussion highlights the practical and emotional aspects of receiving care, including how the treatment setting, whether in a community clinic or academic center, may influence the overall experience. Dr. Morrison guides the conversation to emphasize how individual patient journeys can vary based on treatment pathways and care environments. This segment brings a real-world perspective to advanced melanoma management, helping to contextualize clinical decisions through the lens of patient experience and reinforcing the importance of personalized care.

In this opening segment, Dr. Morrison provides a foundational overview of advanced melanoma, including how metastatic disease is currently defined and how treatment outcomes have evolved over the past decade. He discusses the shift in management driven by the introduction of immune checkpoint inhibitors, which have significantly improved survival outcomes compared with historical expectations. The conversation highlights how advances in therapy have led to more durable responses and better disease control for many patients, while also noting that outcomes can vary based on individual clinical factors. Dr. Morrison emphasizes the importance of understanding the current treatment landscape as a framework for evaluating newer approaches in care. This segment sets the clinical context for the discussion, preparing the audience for a deeper exploration of treatment delivery methods and their implications for patient experience in advanced melanoma.